ArticleImmunology2021
Interleukin-35 is a critical regulator of immunity during helminth infections associated with multiple sclerosis.
Article in Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Comparative analysis of multiple sclerosis burden in China and India from 1990 to 2021 based on the Global Burden of Disease Study 2021.Immunologic research · 2026Article
- Anisakiasis: A Decade of Molecular and Diagnostic Advancements (2015-2026).International journal of molecular sciences · 2026Review
- The role and mechanism of IL‑35 in myasthenia gravis (Review).International journal of molecular medicine · 2026Review
- Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.Neuropsychopharmacology reports · 2025Review
- The Role and Potential Application of IL-12 in the Immune Regulation of Tuberculosis.International journal of molecular sciences · 2025Review
- Regulatory B cells in parasitic infections: roles and therapeutic potential.Parasitology research · 2025Review
- The half-century odyssey of regulatory B cells: from Breg discovery to emerging frontiers.Frontiers in immunology · 2025Review
- High interleukin-35 expression is associated with the severity of rheumatic mitral stenosis.Frontiers in immunology · 2025Article
- Human Ascaris infection is associated with higher frequencies of IL-10 producing B cells.PLoS neglected tropical diseases · 2024Article
- The circulating IL-35Immunity, inflammation and disease · 2024Article
- Evaluation of IL-35, as a Possible Biomarker for Follow-Up after Therapy, in Chronic HumanVaccines · 2023Article
- Interleukin-35 attenuates blood-brain barrier dysfunction caused by cerebral ischemia-reperfusion injury through inhibiting brain endothelial cell injury.Annals of translational medicine · 2022Article
- Elevated IL-35 level and iTr35 subset increase the bacterial burden and lung lesions inOpen life sciences · 2022Article
- Interleukin-35 is a critical regulator of immunity during helminth infections associated with multiple sclerosis.Immunology · 2021Article
- Characterization of Definitive Regulatory B Cell Subsets by Cell Surface Phenotype, Function and Context.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is currently thought to arise by interactions between genetic susceptibility and environmental factors. Infections in general trigger autoimmune responses causing clinical manifestations of disease. However, as a result of regulatory T (Treg)- and regulatory B (Breg)-cell induction, helminth infections tend to dampen disease activity. IL-35, the newest member of the IL-12 family, is an inhibitory cytokine composed of an EBI3β chain subunit, and an IL-12p35 subunit. The aim of this study was to investigate the role of IL-35 during parasite infections occurring in individuals with MS. Numbers of IL-35-producing Breg cells are higher in CSF from helminth-infected than from uninfected MS subjects, a finding associated with decreased MRI disease activity. Interestingly, stimulation of CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.